The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
Prof. Ralf Gold
PeerNow Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
The Diagnostic Challenges of Spinal Cord Lesions in MS
Jiwon Oh, MD, PhD, FRCPC
PeerBenefit/Risk Strategies in Selecting Therapeutic Solutions for MS
Reducing the Burden of MS Treatment
Multiple Sclerosis Physician Resources
Personalized Approach to Managing MS Patients - Dr. Andrew Chan
Optimizing MS Treatment Options
Immunologic Effects on Metabolic Syndrome and MS
Highlights from the MAGNIMS Consensus Guidelines
Establishing Partnerships to Optimize Patient Outcomes
Emerging MRI Techniques in MS Patients
Current and Future MS Treatment Options